# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progress...
"We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constrain...